伊立替康联合卡培他滨治疗晚期结直肠癌的临床观察

目的：观察伊立替康（CPT-11）联合卡培他滨（Capecitabine，希罗达）治疗晚期结直肠癌的疗效及毒性反应。方法：从2004年2月-2006年5月对晚期结直肠癌采用CPT-11联合卡培他滨方案化疗。入组患者均经病理组织学证实，且有可测量病灶。具体方案为：CPT-11250mg／m^2 iv，d1；希罗达1250mg／m^2 po，bid，d1-d14。21天为1个周期，化疗2个周期后评价疗效及毒性反应。结果：可评价疗效者60例，其中完全缓解（CR）4例，部分缓解（PR）22例，有效率（RR）为43．3％，稳定（SD）28例（46．7％），进展（PD）6例（10．0％）。临床受益率为83．3％，疼痛缓解率83．3％。肿瘤中位进展时间7．2个月，中位生存期13．8个月。主要毒副反应为迟发性腹泻和中性粒细胞减少，未出现治疗相关性死亡。结论：CPT-11联合卡培他滨方案治疗晚期结直肠癌患者有较好疗效，毒副反应可以接受。

The clinical observation of irinotecan combined capecitabine for 60 patients with locally advanced or metastatic colorectal cancer

Objective:To investigate the efficacy and toxicity of irinotecan (CPT-11) combined capecitabine for patients with locally advanced or metastatic colorectal cancer.Methods:From February 2004 to May 2006, 60 evaluable patients with locally advanced or metastatic colorectal cancer based chemotherapy received Irinotecan(250mg/m2 iv gtt)on day 1 and capecitabine (1 250mg/m2 po bid) on days 1 to 14, the regimen was repeated every 3 weeks and efficacy and toxicity were evaluated after 2 cycles.Results:In 60 evaluable patients, 4 cases had complete response, 22 cases had partial response, 28 cases had stable disease and 6 cases with progressive disease. The response rate of the whole group was 43.3% and the stability rate was 46.7%. The clinical response rate was 83.3%. Median time to progression was 7.2 months and median overall survival time was 13.8 months. Dose limiting toxicity was delayed diarrhea and neutropenia. There was no death during the treatment.Conclusion:The regimen CPT-11 combined capecitabine is efficacious and tolerable for locally advanced or metastatic colorectal cancer.